Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service breast biopsy & localization cases in Indiana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 86 | 5,705 | 35% |
| 2020 | 77 | 4,968 | 39% |
| 2021 | 83 | 5,120 | 44% |
| 2022 | 80 | 5,081 | 47% |
| 2023 | 68 | 5,054 | 51% |
| 2024 | 62 | 4,663 | 53% |
| 2025 from claims | – | 4,547 4,173–4,811 | 54% |
| 2026 forecast | – | 4,572 4,023–5,276 | 55% |
| 2027 forecast | – | 4,580 3,915–5,458 | 55% |
| 2028 forecast | – | 4,587 3,827–5,616 | 56% |
| 2029 forecast | – | 4,592 3,751–5,759 | 57% |
| 2030 forecast | – | 4,597 3,683–5,891 | 57% |
Image-guided breast biopsy and marker/localization placement. Professional codes (what the surgeon bills): CPT 19081, 19083, 19085, 19281, 19283, 19285.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 44% of the cases CMS names in Indiana; 32 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 85% hospital outpatient, 15% office. The share outside the hospital has moved +7 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 165 | 9,253−2.3%/yr | −2.3%/yr | 7.1 | 8% | 9,520 in 2030+0.5%/yr |
| Ohio | 133 | 7,179−2.5%/yr | −2.5%/yr | 7.0 | 2% | 6,960 in 2030−0.5%/yr |
| Michigan | 102 | 5,736−6.4%/yr | −6.4%/yr | 7.3 | 5% | 5,320 in 2030−1.2%/yr |
| Missouri | 83 | 5,112−2.1%/yr | −2.1%/yr | 8.8 | 2% | 5,760 in 2030+2%/yr |
| Wisconsin | 59 | 3,773−5.8%/yr | −5.8%/yr | 7.2 | 14% | 4,380 in 2030+2.5%/yr |
| Minnesota | 64 | 3,656−3.2%/yr | −3.2%/yr | 8.7 | 38% | 4,430 in 2030+3.2%/yr |
| Iowa | 33 | 2,153−2.2%/yr | −2.2%/yr | 5.1 | 38% | 2,780 in 2030+4.4%/yr |
| Kansas | 31 | 2,002−2.5%/yr | −2.5%/yr | 5.2 | 34% | 2,170 in 2030+1.4%/yr |
| Nebraska | 32 | 1,959−0.6%/yr | −0.6%/yr | 7.9 | 31% | 2,180 in 2030+1.8%/yr |
| South Dakota | 17 | 929−4.9%/yr | −4.9%/yr | 7.5 | 23% | 1,270 in 2030+5.3%/yr |
| North Dakota | 20 | 868+4.3%/yr | +4.3%/yr | 9.1 | 6% | 1,140 in 2030+4.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Tumor & fibroid embolization | 5 | 282+1.3%/yr | +1.3%/yr | 0.40.8× | 61% | 580 in 2030+13%/yr |
| Tumor ablation | 0 | 141+2.6%/yr | +2.6%/yr | 0.20.6× | 0% | 190 in 2030+5.5%/yr |
Breast biopsy & localization in every state, and its device makers · Every procedure market in Indiana · Every state · Compare with Illinois
Exact Sciences leads with 53% of company spending on these surgeons in 2025, +5 pts on 2024.
In 2025, 16 companies reported engagement with Indiana’s surgeons worth $166K in consulting, speaking, meals and travel tied to these products, about $2,677 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.